Patent Expiration Does Not Signal a Savings Date, Cautions SHARx’s Paul Pruitt

health news

Patent expiration doesn’t necessarily mean savings are right around the corner. SHARx’s Paul Pruitt says employers need a pharmacy strategy for the costs they face today and the potential for high-price options to emerge before the generics hit the shelves. 

ST. LOUIS, Nov. 16, 2026 /PRNewswire/ — A drug nearing patent expiration may seem like relief from high prices, but lower-cost competition can still take years to reach the market.

"In simple terms, no one should build a pharmacy budget assuming that patent expiration automatically means lower costs next year or even the year after. We know what the results are only when competition does enter the market. The longer meaningful competition is delayed, the longer employers and patients are left managing the higher cost of the existing therapy.” - Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx

Employers cannot control when a patent expires, a lawsuit is resolved, or when a biosimilar reaches the market. They can, however, evaluate how their pharmacy benefits are structured and what options are available to manage prescription costs today.

“Adalimumab shows how long U.S. employers can wait for lower-cost competition; approximately six and a half years passed between approval of the first biosimilar and its U.S. launch. In other markets, the wait was about two years, so we know the timeline could be shorter,” Pruitt noted.

Setting New Timetables

“What’s more is that, in the U.S., drugmakers have other ways to keep generics out of patients’ hands.” Pruitt explains how, even after a patent’s time is up, drugmakers may make minimal adjustments to the same drug or launch a new drug that treats the same condition(s) as the old drug. These moves reset the patent clock on the new, high-priced version of the medication while heavily marketing the new version to doctors and patients.”

Patent Expiration Does Not Signal a Savings Date

These delays are fueled by several factors. Manufacturers can use multiple strategies to protect market share after the initial patent, including overlapping patents, modified versions of existing products, and the launch of replacement medications. These gaps can leave employers knowing that a major biologic is approaching the end of patent protection without knowing when a competing product will reach the market or at what price.  

“What does that delay mean? In simple terms, no one should build a pharmacy budget assuming that patent expiration automatically means lower costs next year or even the year after. We know what the results are only when competition does enter the market,” Pruitt said. “The longer meaningful competition is delayed, the longer employers and patients are left managing the higher cost of the existing therapy.”

Employers Still Have Decisions to Make

Pruitt encourages employers to examine how the pharmacy benefit manager (PBM) defines value and how formulary decisions align with the plan’s lowest net cost. He also recommends looking beyond typical discounts and rebates to understand the actual net cost of medications and whether their members can be directed towards clinically appropriate, lower-cost options.

“It starts with asking, ‘Are the PBM’s incentives and formulary decisions actually aligned with the employer’s lowest net cost?'” Pruitt said. “Plan design is another area to review when several effective treatments are available. For conditions which have multiple effective treatments, ask whether there is a plan to encourage the higher-value options.” Pruitt said. “There may be medications that are equally effective for some patients but much less expensive.”

Competition Has to Produce Measurable Savings

Biosimilar competition is another factor that can produce significant savings when it reaches the market. Kaiser Permanente reported that biosimilars typically cost about 30% less than their brand-name biologic counterparts and reduced U.S. drug spending by an estimated $20 billion in 2024.

Pruitt said policymakers should protect incentives for pharmaceutical innovation while ensuring competition can reach employers and patients within a reasonable time frame.

“Patents are designed to give manufacturers a reward for innovation, but drug patents have not been that straightforward,” Pruitt said. “Once competition exists, market forces work great. The problem comes when competition is not allowed to function.”

About SHARx

SHARx is a procurement and supply chain management solution for high-cost prescription drugs. Working alongside employer-sponsored health plans, SHARx helps employers address the financial impact of expensive and specialty medications while providing members with personalized advocacy and access to cost-effective sourcing solutions. Learn more at SHARXplan.com 

References

  • Amgen. (2023, January 31). AMJEVITA™ (adalimumab-atto), first biosimilar to HUMIRA®, now available in the United States.
  • Bettelheim, A. (2026, September 15). Biosimilars stuck in a rut. Axios.
  • Hayes, M. (2026, September 25). Want to lower drug prices? Reform the U.S. patent system. Kaiser Permanente.
  • Purvis, L., Kaltenboeck, A., & Chen, J. (2026, September 22). No easy solutions: Brand name drug companies have many ways to slow generic competition. AARP Public Policy Institute.

Media inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629
Jotopr.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/patent-expiration-does-not-signal-a-savings-date-cautions-sharxs-paul-pruitt-302939902.html

SOURCE SHARx

Iframe sync
error: Content is protected !!